Скачать с ютуб Computational Antibody Discovery Symposium: Dr. Sandeep Kumar в хорошем качестве

Computational Antibody Discovery Symposium: Dr. Sandeep Kumar

Computational Antibody Discovery: State of the Art Symposium, June 22, 2023, Biopharmaceutical Informatics: Syncretic use of computation and experimentation in discovery and development of biotherapeutics - Sandeep Kumar, Boehringer Ingelheim In this talk, Dr. Kumar will describe case studies of computation and experimentation working together at different stages of discovery and development of antibody-based biotherapeutics. Sandeep Kumar holds a Ph.D. in Computational Biophysics from Indian Institute of Science and has over 20 years of experience researching protein structure – function relationships using computational means. Dr. Kumar has so far contributed to ~100 research articles, reviews, book chapters, and edited a book entitled “Developability of Biotherapeutics: Computational Approaches”. In 2014, Sandeep Kumar received the Ebert Prize from the American Pharmacist Association (APhA) for the discovery of aggregation – immunogenicity coupling in biotherapeutics. Dr. Kumar has also contributed towards development of several antibody-based biotherapeutics and a vaccine currently on the market. After joining Boehringer-Ingelheim in 2018, Dr. Kumar has been contributing towards discovery of several monoclonal antibodies as well as multi-specific modalities that are currently in development. Using the insights gained from these experiences, Dr. Kumar has been advocating for Biopharmaceutical Informatics, a strategic vision dedicated to synergistic use of computation and experimentation towards a cost effective and more efficient discovery and development of biotherapeutics. In his talk, Dr. Kumar describes case studies of computation and experimentation working together at different stages of discovery and development of antibody-based biotherapeutics. Symposium Agenda Introduction - Janice Reichert (The Antibody Society); Konrad Krawczyk (Natural Antibody); Andrew Buchanan (AstraZeneca) Speaker 1) Pietro Sormanni (University of Cambridge). Third-generation approaches of antibody discovery and optimization 2) Tzvika Hartman (Biolojic Design). AI-driven design of smart therapeutics 3) Victor Greiff (University of Oslo). Computational developability profiling of antibody repertoire data 4) Sandeep Kumar (Boehringer Ingelheim). Biopharmaceutical Informatics: Syncretic use of computation and experimentation in discovery and development of biotherapeutics 5) Ben Holland (Antiverse). Machine learning-based design of antibodies against difficult targets Panel discussion Conclusion - Andrew Buchanan (AstraZeneca)